SCOPUS 정보 검색 플랫폼

1
- 85029007717
- Heart disease and stroke statistics-2017 update: a report from the American Heart Association
- Benjamin, EJ, Blaha, MJ, Chiuve, SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation 135 (2017), e146–e603.
- (2017) Circulation , vol.135 , pp. e146-e603
- Benjamin, E.J.¹ Blaha, M.J.² Chiuve, S.E.³

2
- 84962888031
- Pathophysiology of myocardial infarction
- Frangogianis, NG, Pathophysiology of myocardial infarction. Comp Physiol 5 (2015), 1841–1875.
- (2015) Comp Physiol , vol.5 , pp. 1841-1875
- Frangogianis, N.G.¹

3
- 65849268320
- Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials
- Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
- (2009) Lancet , vol.373 , pp. 1849-1860

4
- 0037454050
- Oral anticoagulants in patients with coronary artery disease
- Anand, SS, Yusuf, S, Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 41:suppl S (2003), 62S–69S.
- (2003) J Am Coll Cardiol , vol.41 , pp. 62S-69S
- Anand, S.S.¹ Yusuf, S.²

5
- 79952496003
- Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies
- Turpie, AG, Lassen, MR, Eriksson, BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105 (2011), 444–453.
- (2011) Thromb Haemost , vol.105 , pp. 444-453
- Turpie, A.G.¹ Lassen, M.R.² Eriksson, B.I.³

6
- 84859385808
- Oral rivaroxaban for the treatment of symptomatic pulmonary embolism
- Buller, HR, Prins, MH, Lensing, AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366 (2012), 1287–1297.
- (2012) N Engl J Med , vol.366 , pp. 1287-1297
- Buller, H.R.¹ Prins, M.H.² Lensing, A.W.³

7
- 78650619315
- Oral rivaroxaban for symptomatic venous thromboembolism
- Bauersachs, R, Berkowitz, SD, Brenner, B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363 (2010), 2499–2510.
- (2010) N Engl J Med , vol.363 , pp. 2499-2510
- Bauersachs, R.¹ Berkowitz, S.D.² Brenner, B.³

8
- 80052592404
- Rivaroxaban versus warfarin in non-valvular atrial fibrillation
- Patel, MR, Mahaffey, KW, Garg, J, et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
- (2011) N Engl J Med , vol.365 , pp. 883-891
- Patel, M.R.¹ Mahaffey, K.W.² Garg, J.³

9
- 80052162121
- Apixaban with antiplatelet therapy after acute coronary syndrome
- Alexander, JH, Lopes, RD, James, S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med 365 (2011), 699–708.
- (2011) N Engl J Med , vol.365 , pp. 699-708
- Alexander, J.H.¹ Lopes, R.D.² James, S.³

10
- 84862907587
- Rivaroxaban in patients with a recent acute coronary syndrome
- Mega, JL, Braunwald, E, Wiviott, SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366 (2012), 9–19.
- (2012) N Engl J Med , vol.366 , pp. 9-19
- Mega, J.L.¹ Braunwald, E.² Wiviott, S.D.³

11
- 33645861080
- Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
- Bhatt, DL, Fox, KA, Hacke, W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006), 1706–1717.
- (2006) N Engl J Med , vol.354 , pp. 1706-1717
- Bhatt, D.L.¹ Fox, K.A.² Hacke, W.³

12
- 84928944621
- Long-term use of ticagrelor in patients with prior myocardial infarction
- Bonaca, MP, Bhatt, DL, Cohen, M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 372 (2015), 1791–1800.
- (2015) N Engl J Med , vol.372 , pp. 1791-1800
- Bonaca, M.P.¹ Bhatt, D.L.² Cohen, M.³

13
- 85026258046
- Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial
- Bosch, J, Eikelboom, JW, Connolly, SJ, et al. Rationale, design and baseline characteristics of participants in the cardiovascular outcomes for people using anticoagulation strategies (COMPASS) trial. Can J Cardiol 33 (2017), 1027–1035.
- (2017) Can J Cardiol , vol.33 , pp. 1027-1035
- Bosch, J.¹ Eikelboom, J.W.² Connolly, S.J.³

14
- 85029804845
- Rivaroxaban with and without aspirin in stable coronary or peripheral artery disease
- Eikelboom, J, Connolly, SJ, Bosch, J, et al. Rivaroxaban with and without aspirin in stable coronary or peripheral artery disease. N Engl J Med 377 (2017), 1319–1330.
- (2017) N Engl J Med , vol.377 , pp. 1319-1330
- Eikelboom, J.¹ Connolly, S.J.² Bosch, J.³

15
- 84867740025
- Third universal definition of myocardial infarction
- Thygesen, K, Alpert, JS, Jaffe, AS, Simoons, ML, Chaitman, BR, White, HD, Third universal definition of myocardial infarction. Eur Heart J 33 (2012), 2551–2567.
- (2012) Eur Heart J , vol.33 , pp. 2551-2567
- Thygesen, K.¹ Alpert, J.S.² Jaffe, A.S.³ Simoons, M.L.⁴ Chaitman, B.R.⁵ White, H.D.⁶

16
- 79959728931
- Landmark analysis at the 25-year landmark point
- Dafni, U, Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes 4 (2011), 363–371.
- (2011) Circ Cardiovasc Qual Outcomes , vol.4 , pp. 363-371
- Dafni, U.¹

17
- 85020692248
- Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study
- Li, L, Geraghty, OC, Mehta, Z, Rothwell, PM, Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 390 (2017), 490–499.
- (2017) Lancet , vol.390 , pp. 490-499
- Li, L.¹ Geraghty, O.C.² Mehta, Z.³ Rothwell, P.M.⁴

18
- 84933673677
- Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials
- Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials. Lancet 385 (2015), 1397–1405.
- (2015) Lancet , vol.385 , pp. 1397-1405

19
- 0034688194
- Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
- Heart Outcomes Prevention Evaluation Study Investigators, Yusuf, S, Sleight, P, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000), 145–153.
- (2000) N Engl J Med , vol.342 , pp. 145-153
- Yusuf, S.¹ Sleight, P.²

20
- 84966570190
- Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54
- Bonaca, MP, Bhatt, DL, Steg, G, et al. Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54. Eur Heart J 37 (2016), 1133–1142.
- (2016) Eur Heart J , vol.37 , pp. 1133-1142
- Bonaca, M.P.¹ Bhatt, D.L.² Steg, G.³

21
- 34247869852
- Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
- Bhatt, DL, Flather, MD, Hacke, W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49 (2017), 1982–1988.
- (2017) J Am Coll Cardiol , vol.49 , pp. 1982-1988
- Bhatt, D.L.¹ Flather, M.D.² Hacke, W.³

22
- 84883001308
- Polypill for cardiovascular disease prevention—reply
- Smith, R, McCready, T, Yusuf, S, Polypill for cardiovascular disease prevention—reply. JAMA 310 (2013), 749–750.
- (2013) JAMA , vol.310 , pp. 749-750
- Smith, R.¹ McCready, T.² Yusuf, S.³